Accumulation of Unusual Gangliosides GQ3 and GP3 in Breast Cancer Cells Expressing the GD3 Synthase

Agata Steenackers 1,†, Jorick Vanbeselaere 1,†, Aurélie Cazet 1,‡, Marie Bobowski 1, Yoann Rombouts 1,#, Florent Colomb 1, Xuefen Le Bourhis 2, Yann Guérardel 1 and Philippe Delannoy 1,*

1 Structural and Functional Glycobiology Unit, UMR CNRS 8576, University of Sciences and Technologies of Lille, 59655 Villeneuve d’Ascq, France; E-Mails: agata.steenackers@hotmail.fr (A.S.); jorick.vanbeselaere@gmail.com (J.V.); aurelie_cazet@yahoo.fr (A.C.); marie.bobowski@hotmail.fr (M.B.); yoann.rombouts@gmail.com (Y.R.); florent.colomb@ed.univ-lille1.fr (F.C.); yann.guerardel@univ-lille1.fr (Y.G.)

2 INSERM U908, University of Sciences and Technologies of Lille, 59655 Villeneuve d’Ascq, France; E-Mail: xuefen.lebourhis@univ-lille1.fr

† These authors contributed equally to this work.

‡ Current address: Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia

# Current address: Department of Rheumatology, Leiden University Medical Center, 2300 RC Leiden, The Netherlands

* Author to whom correspondence should be addressed; E-Mail: philippe.delannoy@univ-lille1.fr; Tel.: +33-320-436-923; Fax: +33-320-436-555.

Received: 18 June 2012; in revised form: 20 July 2012 / Accepted: 6 August 2012 / Published: 10 August 2012

Abstract: Glycosphingolipids from the ganglio-series are usually classified in four series according to the presence of 0 to 3 sialic acid residues linked to lactosylceramide. The transfer of sialic acid is catalyzed in the Golgi apparatus by specific sialyltransferases that show high specificity toward glycolipid substrates. ST8Sia I (EC 2.4.99.8, SAT-II, SIAT 8a) is the key enzyme controlling the biosynthesis of b- and c-series gangliosides. ST8Sia I is expressed at early developmental stages whereas in adult human tissues, ST8Sia I transcripts are essentially detected in brain. ST8Sia I together with b- and c-series
gangliosides are also over-expressed in neuroectoderm-derived malignant tumors such as melanoma, glioblastoma, neuroblastoma and in estrogen receptor (ER) negative breast cancer, where they play a role in cell proliferation, migration, adhesion and angiogenesis. We have stably expressed ST8Sia I in MCF-7 breast cancer cells and analyzed the glycosphingolipid composition of wild type (WT) and GD3S+ clones. As shown by mass spectrometry, MCF-7 expressed a complex pattern of neutral and sialylated glycosphingolipids from globo- and ganglio-series. WT MCF-7 cells exhibited classical monosialylated gangliosides including G_{M3}, G_{M2}, and G_{M1a}. In parallel, the expression of ST8Sia I in MCF-7 GD3S+ clones resulted in a dramatic change in ganglioside composition, with the expression of b- and c-series gangliosides as well as unusual tetra- and pentasialylated lactosylceramide derivatives G_{Q3} (II\text{\textsuperscript{3}}Neu5Ac\text{\textsubscript{2}}-Gg2Cer) and G_{P3} (II\text{\textsuperscript{3}}Neu5Ac\text{\textsubscript{2}}-Gg2Cer). This indicates that ST8Sia I is able to act as an oligosialyltransferase in a cellular context.

**Keywords:** gangliosides; GD3 synthase; MCF-7; unusual gangliosides

---

**Abbreviations:** BSA: Bovine Serum Albumin; Cer: ceramide; DMB: 1,2-diamino-4,5-methylenedioxybenzene; DMEM: Dulbecco’s Modified Eagle’s Medium; EDTA: Ethylenediaminetetraacetic Acid; DMSO: Dimethyl Sulfoxide; FBS: Fetal Bovine Serum; FITC: Fluorescein Isothiocyanate; FL-HPLC: Fluorescence Detection High Performance Liquid Chromatography; GD3S: GD3 synthase; GSL: glycosphingolipid; HPRT: Hypoxanthine PhosphoRibosylTransferase; HRP: horseradish peroxidase; LacCer: Lactosylceramide; mAb: monoclonal Antibody; MALDI-TOF: matrix assisted laser desorption-ionization time-of-flight; MS: Mass Spectrometry; PBS: Phosphate Buffered Saline; QPCR: Quantitative real-time Polymerase Chain Reaction; SDS-PAGE: Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis; ST3Gal V: G_{M3} synthase; ST8Sia I: GD3 synthase; ST8Sia V: GT3 synthase; WT: Wild Type.

### 1. Introduction

Glycosphingolipids (GSL) from the ganglio-series are classified in four series according to the presence of 0 to 3 sialic acid residues linked to lactosylceramide (Gal\text{\textbeta}1-4Glc-Cer, LacCer) [1]. The transfer of sialic acid to LacCer is catalyzed in the Golgi apparatus by specific sialyltransferases (namely ST3Gal V, ST8Sia I and ST8Sia V) that show high specificity toward glycolipid substrates [2]. LacCer, G_{M3} (Neu5Ac\text{\textalpha}2-3Gal\text{\textbeta}1-4Glc-Cer, II\text{\textsuperscript{3}}Neu5Ac\text{\textalpha}1-Gg2Cer), G_{D3} (Neu5Ac\text{\textalpha}2-8Neu5Ac\text{\textalpha}2-3Gal\text{\textbeta}1-4Glc-Cer, II\text{\textsuperscript{3}}Neu5Ac\text{\textalpha}2-Gg2Cer) and G_{T3} (Neu5Ac\text{\textalpha}2-8Neu5Ac\text{\textalpha}2-3Gal\text{\textbeta}1-4Glc-Cer, II\text{\textsuperscript{3}}Neu5Ac\text{\textalpha}3-Gg2Cer) are therefore the precursors for 0-, a-, b- and c-series gangliosides and the biosynthesis of these compounds determine the relative proportion of gangliosides in each series (Figure 1). Elongation of the precursors can then occur by the sequential action of N-acetyl-galactosaminyltransferase (β4GalNAc T1), galactosyltransferase (β3Gal T4) and sialyltransferases (ST3Gal I, ST3Gal II and ST8Sia V), α-gangliosides deriving from the action of ST6GalNAc III, V or VI on G_{M1b}, G_{D1a} or G_{T1b} (Table 1).
**Figure 1.** Biosynthesis pathway for gangliosides. The code names of gangliosides are according to Svennerholm [1]. Cer: ceramide.

The sialyltransferase ST8Sia I (EC 2.4.99.8, SAT-II, SIAT 8a) is the only enzyme known to catalyze the transfer of a sialic acid residue onto GM₃ through an α₂,8-linkage to synthesize GD₃. ST8Sia I and GD₃ are expressed in fetal tissues at an early developmental stage [3,4] where they play a key role in cell-cell interaction, cell differentiation and proliferation [5], whereas in adult human tissues, ST8Sia I is essentially detected in the brain [6]. ST8Sia I and GD₃ have been also shown to be over-expressed in neuroectoderm-derived malignant tumors such as melanoma, glioblastoma and neuroblastoma, and in estrogen receptor negative breast cancer [7–10].
Table 1. Glycosyltransferases involved in gangliosides biosynthesis. R = GA3, GM3, GD3 or GT3.

| Gene    | Common name | Main acceptor(s) | Accession # | Reference |
|---------|-------------|------------------|-------------|-----------|
| UGCG    | GlcCer synthase | Ceramide | NM_003358  | [18]      |
| B4GALT6 | LacCer synthase | Glucosylceramide | NM_004775 | [19,20]   |
| ST3GAL5 | GM3 synthase | Lactosylceramide | NM_003896  | [21]      |
| ST8S1A1 | GD3 Synthase | GM3, GD3 | NM_003034.2 | [11–13] |
| ST8S1A5 | GT3 Synthase | GD3, GM1b, GD1a, GT1b | NM_013305  | [17]      |
| B4GALNACT1 | GM2/GD2 synthase | G3A3, GM3, GD3, GT3 | NM_001478.2 | [22–24]   |
| B3GALT4 | ST3Gal I | Galβ1-3GalNAcβ1-4-R | NM_003033  | [26]      |
| ST3GAL1 | ST3Gal II | Galβ1-3GalNAcβ1-4-R | NM_006927  | [27]      |
| ST6GALNAC3 | ST6GalNAc III | Neu5Acα2-3Galβ1-3GalNAcβ1-4-R | NM_152996 | [28]      |
| ST6GALNAC5 | ST6GalNAc V | Neu5Acα2-3Galβ1-3GalNAcβ1-4-R | NM_030965.1 | [29]      |
| ST6GALNAC6 | ST6GalNAc VI | Neu5Acα2-3Galβ1-3GalNAcβ1-4-R | NM_013443.3 | [29]      |

The human ST8Sia I cDNA was simultaneously isolated by expression cloning by three research groups [11–13]. The ST8SIA1 gene is located on chromosome 12, in p12.1-p11.2 and consists of five coding exons spanning over 135 kbp of genomic DNA [14]. ST8Sia I cDNA encodes a 341 amino acid membrane-bound Golgi enzyme with a 12 amino-acid cytoplasmic tail, a transmembrane domain of about 20 residues and a catalytic domain containing the conserved Sialyl motifs involved in substrate binding and transfer [15].

Whereas ST8Sia I mainly sialylates GM3, Nakayama and co-workers have underlined its ability to synthesize GT3 from GD3 [6]. ST8Sia I was also shown to use GM1b, GD1a or GT1b as acceptor substrates to synthesize GD1c, GT1a or GQ1b, respectively, both in vitro and in vivo [16]. However, the α2,8-sialyltransferase ST8Sia V is a much better candidate for GT1a/GQ1b synthase activity [17] and no ST8Sia V activity was detected toward GM3. Consequently, ST8Sia I is considered as the only GD3 synthase (GD3S) that controls the biosynthesis of gangliosides from the b- and c-series.

By stable transfection of the full-length cDNA of human GD3 synthase, we have isolated cellular clones deriving from MCF-7 breast cancer cells that constitutively express GD3S together with b- and c-series gangliosides. Here, we show by mass spectrometry and HPLC analysis that clones that express a high level of GD3S also accumulate unusual tetra- and pentasialylated derivatives of LacCer, GQ3 (II5Neu5Ac4-Gg2Cer) and GP3 (II5Neu5Ac5-Gg2Cer).

2. Results and Discussion

2.1. Analysis of ST8Sia I Expression by QPCR in Control and GD3S+ MCF-7 Clones

MCF-7 cells were transfected with the pcDNA3-GD3S expression vector containing the full-length cDNA of human GD3S or the empty pcDNA3 vector as control. Transfected cells were cultured 21 days in the presence of 1 mg/mL G418. Individual G418-resistant colonies were isolated by limiting dilution cloning. Forty-four clones were obtained and analyzed for the expression of GD3S. As previously shown [30], QPCR analysis of GD3S expression (Figure 2) indicates that GD3S mRNA is express at a very low level in wild-type and control (empty vector transfected) MCF-7 cells compared to SK-Mel 28 melanoma cells used as positive control [31]. Within the forty-four analyzed clones,
three GD3S+ clones (clone #31, #41 and #44) were selected according to the high expression of GD3S compared to SK-Mel 28 (1.3-fold, 2.3-fold and 6.3-fold, respectively) (Figure 2).

**Figure 2.** QPCR analysis of GD3S expression in control and GD3S+ MCF-7 clones. Quantification of GD3S expression was performed by the method described by Livak and Schmittgen [32] and normalized to HPRT. The expression of GD3S in MCF-7 cells was relative to SK-Mel 28, which was regarded as 100%.

2.2. Flow Cytometry Analysis of Gangliosides Expression in MCF-7 GD3S+ Clones

The pattern of gangliosides was monitored in the three selected MCF-7 GD3S+ clones (clone #31, #41, #44) by flow cytometry using anti-GD3 R24 and anti-GT3 A2B5 mAbs. As shown in Figure 3, the three GD3S+ clones expressed GD3 and GT3 whereas wild-type and control (empty vector transfected) MCF-7 cells did not express complex gangliosides. GT3 is expressed at a similar level in the three GD3S+ clones but a decrease of GD3 is observed in clone #44 compared to clone #31 and #41 whereas the expression level of GD3S was 4.8-fold or 2.7-fold higher in clone #44 compared to clone #31 and #41, respectively (Figure 2). Control cells showed no change in the ganglioside profile compared with wild-type MCF-7 (data not shown).

2.3. MS Analysis of Gangliosides in MCF-7 and GD3S+ Clones

Glycolipids were extracted from cells, purified by reverse phase chromatography and permethylated prior to MS analysis. Mass spectrometry analysis established that glycolipid profiles of MCF-7 WT and GD3S+ clones were characterized by complex patterns of neutral and sialylated glycosphingolipids from globo- and ganglio-series. Profiles of all cell lines were dominated by two signals at m/z 1460 and 1572 both identify based on their MALDI-TOF/TOF fragmentation patterns (data not shown) and in agreement with previously published analyses [33] as mixtures of Gb4 and G_{A1} differing by the nature of their lipid moieties (d18:1-16:0 or d18:1-24:0). Along these two major components, MS and MS/MS analyses permitted us to identified other minor neutral GSLs including LacCer and G_{b3} (Figure 4). The comparison of MS profiles did not show any significant difference in neutral GSLs content between MCF-7 WT and GD3+ clones. On the contrary, the content in sialylated
glycolipids varied among the different cell lines. MCF-7 WT cells exhibited monosialylated gangliosides including \( \text{G}_\text{M3}, \text{G}_\text{M2}, \) and \( \text{G}_\text{M1} \). The only disialylated GSL observed in MCF-7 WT cells was \( \text{GD1} \) at \( m/z \) 2182 and 2194. Its sequence analysis by MALDI-TOF/TOF typified it as \( \text{GD1a} \), thus lacking disialylated motif (data not shown). GD3+ clones did not show GSLs from the G2 and G1 families but synthesized instead a family of unusual highly sialylated lactosylceramide derivatives substituted by up to 5 Neu5Ac residues tentatively identified as \( \text{GD3}, \text{GT3}, \text{GQ3} \) and \( \text{GP3} \). The structure of these four compounds was confirmed by MALDI-TOF/TOF sequencing.

**Figure 3.** Flow cytometry analysis of gangliosides in pcDNA3-GD3S transfected MCF-7 cells. Immunodetection of \( \text{GD3} \) and \( \text{GT3} \) was performed using anti-\( \text{GD3} \) R24 (dilution 1:100) and anti-\( \text{GT3} \) A2B5 (dilution 1:10) mAbs. The gray peaks correspond to the negative controls (incubation with secondary antibody alone, anti-mouse IgM or anti-mouse IgG labeled with Alexa 488).

The Glycolipid profile of SK-Mel 28 cells was also analyzed in respect to the presence of polysialylated lactosylceramide derivatives. Contrarily to MCF-7 WT cells, GSLs extracted from SK-Mel 28 cells did not contain globo-series but were dominated by ganglio-series, which induces much higher overall sialic acid content (data not shown). In particular, disialylated \( \text{GD3} \) appears to be the major component along with monosialylated \( \text{GM3} \) and trisialylated \( \text{GT3} \). However, the tetra- and pentasialylated gangliosides synthesized by MCF-7 GD3+ clones were not detected in SK-Mel 28.

**Figure 4.** Comparison of MS profiles of permethylated glycosphingolipids purified from MCF-7 WT and GD3S+ clone #44. All GSLs are present as d18:1/C16:0 (Cer*) and d18:1/C24:0 (Cer**) isomers. \( \bigcirc \), Gal; \( \bullet \), Glc; \( \blacksquare \), GalNAc; \( \blacklozenge \), Neu5Ac.
We illustrate the sequence analyses of unusual G\textsubscript{Q3} and G\textsubscript{P3} in Figure 5. These two molecules differing in the presence of a single Neu5Ac residue were structurally related. They shared the fragmentation pattern of a linear stretch of four sialic acid residues in terminal non-reducing position as [M+Na]\textsuperscript{+} B-ions at m/z 398, 759, 1120 and 1481 and a linear sequence of Sia\textsubscript{4}Hex\textsubscript{2}Cer at reducing end as [M+Na]\textsuperscript{+} Y-ions at m/z 1106, 1466, 1827 and 2188. G\textsubscript{P3} showed additional B and Y ions at m/z 1842 and 2551 typifying a linear Sia\textsubscript{5} sequence. Altogether, these data established that MCF-7 GD3+ clone #44 synthesizes an unusual family of oligosialylated lactosylceramide derivatives presented from 2 to 5 Neu5Ac residues. The disappearance of G\textsubscript{M2}, G\textsubscript{M1} and G\textsubscript{D1a} in MCF-7 GD3+ clone #44 could be explained by the depletion of G\textsubscript{M3} substrate caused by the over-expression of the GD3S+ that competes with \(\beta\)-4GalNAcT1 for the use of G\textsubscript{M3} substrate.

**Figure 5.** MS/MS sequencing of permethylated glycosphingolipids. Analysis of G\textsubscript{Q3} at m/z 2568 (A) and G\textsubscript{P3} at m/z 2929 (B) with ceramide moieties d18:1/C24:0 (Cer**). All fragments are observed as [M+Na]\textsuperscript{+} adducts except those at m/z at 376 and 660 observed as [M+H]\textsuperscript{+} adducts. Fragment ions were annotated according to nomenclature of Domon and Costello [34]. O, Gal; ●, Glc; ■, GalNAc; ◊, Neu5Ac.
2.4. Quantification of Polysialylation Associated with Gangliosides by HPLC

Because mass spectrometry does not provide reliable quantitative data, we quantified the extent of oligosialylation modifications in GSLs induced by the overexpression of GD3 in MCF-7 by screening all three GD3S+ clones (#31, #41 and #44) (Figure 6). To do that, oligosialylated motifs were released from purified GSLs by mild hydrolysis according to optimized procedures [35] and labeled by DMB before separation and quantification by FL-HPLC [36]. The analysis of relative quantifications of sialic acid chains in GSLs of all MCF-7 GD3S+ clones compared to MCF-7 WT demonstrated a sharp increase of sialylation oligomerization degree, up to five residues, in accordance with mass spectrometry analysis. In MCF-7 WT, no oligosialylation could be observed, in accordance with the sole identification of GD1a by MS. In contrast, all GD3S+ clones contained about 30% of Sia2 and Sia3 motifs, up to 10% of Sia4 and up to 5% of Sia5. Although clones presented similar GSL oligosialylation profiles, small scale quantitative differences could be observed between the three clones, with a prevalence of higher DP values for clone #44 compared to clones #31 and #41.

Figure 6. Relative quantification of oligosialylation sequence on GSL of MCF-7 WT GD3S+ clones #31, clone #41 and clone #44 by FL-HPLC after DMB derivation.

3. Experimental Section

3.1. Antibodies and Reagents

Anti-GD3 R24 mAb was purchased from Abcam (Cambridge, UK) and anti-GT3 A2B5 mAb was kindly provided by Pr. Jacques Portoukalian (Depart. of Transplantation and Clinical Immunology, Claude Bernard University and Edouard Herriot Hospital, Lyon, France). FITC-conjugated sheep anti-mouse IgG was from GE Healthcare (Templemars, France). FITC-conjugated anti-mouse IgM was purchased from Molecular Probes (Invitrogen, Carlsbad, CA, USA).

3.2. Cell Culture

The breast cancer cell line MCF-7 and the melanoma cell line SK-Mel 28 were obtained from the American Type Cell Culture Collection. Cell culture reagents were purchased from Lonza.
Cells were routinely grown in monolayer and maintained at 37 °C in an atmosphere of 5% CO₂, in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and 100 units/mL penicillin-streptomycin. GD3S positive (GD3S+) MCF-7 clones were obtained by stable transfection of the pcDNA3-GD3S expression vector encoding the full-length human GD3 synthase [37] as previously described [33]. Individual resistant colonies were isolated by limit dilution. Three positive clones (#31, #41 and #44), expressing different levels of GD3S were used for further study. Control cells (empty vector transfected) and GD3S+ clones were cultured in the presence of 1 mg/mL G418 (Invitrogen, Cergy-Pontoise, France).

3.3. Quantitative Real-Time-PCR (QPCR) Analysis of GD3 Synthase

Total RNA was extracted using the Nucleospin RNA II kit (Macherey Nagel, Hoerdt, France), quantified using a NanoDrop spectrophotometer (Thermo Scientifics, Wilmington, USA) and the purity of the preparation was checked by ratio of the absorbance at 260 and 280 nm. The cDNA was synthesized using 2 µg of RNA (GE Healthcare). PCR primers for GD3S and Hypoxanthine PhosphoribosylTransferase (HPRT) were previously described [30,38] and synthesized by Eurogentec (Seraing, Belgium). PCR reactions (25 µL) were performed using 2X SYBR® Green Universal QPCR Master Mix (Stratagene, Amsterdam, The Netherlands), with 2 µL of cDNA solution and 300 nM final concentration of each primer. PCR conditions were as follows: 95 °C for 30 s, 51 °C for 45 s, 72 °C for 30 s (40 cycles). Assays were performed in triplicate and GD3S transcript expression level was normalized to HPRT using the 2^{-ΔΔCt} method described by Livak and Schmittgen [32]. Serial dilutions of the appropriate positive control cDNA sample were used to create standard curves for relative quantification and negative control reactions were performed by replacing cDNA templates by sterile water.

3.4. Analysis of Cell Surface Ganglioside by Flow Cytometry

Cells were washed in cold PBS and detached by EDTA 2 mM. Cells were incubated at 4 °C during 1 h with anti-GD3 R24 (1:100) and anti-GT3 A2B5 (1:10), diluted in phosphate buffered saline (PBS) containing 0.5% bovine serum albumin (PBS-BSA) (Sigma-Aldrich). After washing with PBS-BSA, cells were incubated on ice during 1 h with Alexa Fluor 488 anti-IgG or anti-IgM (1:500). After two washes in PBS-BSA, cells were analyzed by flow cytometry (FACScalibur, Becton Dickinson). Control experiments were performed using secondary antibody alone.

3.5. Extraction and Preparation of Glycolipids

Twenty dishes (10 cm diameter) of cultured cells were washed twice with ice-cold PBS and cells were scraped and sonicated on ice in 200 µL of water. The resulting material was dried under vacuum and sequentially extracted by CHCl₃/CH₃OH (2:1, v/v), CHCl₃/CH₃OH (1:1, v/v) and CHCl₃/CH₃OH/H₂O (1:2:0.8, v/v/v). Supernatants were pooled, dried and subjected to a mild saponification in 0.1 M NaOH in CHCl₃/CH₃OH (1:1) at 37 °C for 2 h and then evaporated to dryness [39]. Samples were reconstituted in CH₃OH/H₂O (1:1, v/v) and applied to a reverse phase C₁₈
cartridge (Waters, Milford, MA, USA) equilibrated in the same solvent. After washing with CH$_3$OH/H$_2$O (1:1, v/v), GSLs were eluted by CH$_3$OH, CHCl$_3$/CH$_3$OH (1:1, v/v) and CHCl$_3$/CH$_3$OH (2:1, v/v).

3.6. Mass Spectrometry Analysis of GSL

Prior to mass spectrometry analysis, GSL were permethylated according to Ciucanu and Kerek [40]. Briefly, compounds were incubated 2 h in a suspension of 200 mg/mL NaOH in dry DMSO (300 µL) and CH$_3$I (200 µL). The methylated derivatives were extracted in CHCl$_3$ and washed several times with water. The reagents were evaporated and the sample was dissolved in CHCl$_3$ in the appropriate dilution. MALDI-MS and MS/MS analyses of permethylated GSL were performed on 4800 Proteomics Analyzer (Applied Biosystems, Framingham, MA, USA) mass spectrometer, operated in the reflectron mode. For MS acquisition, 5 µL of diluted permethylated samples in CHCl$_3$ were mixed with 5 µL of 2,5-dihydroxybenzoic acid matrix solution (10 mg/mL dissolved in CHCl$_3$/CH$_3$OH (1:1, v/v)). The mixtures (2 µL) were then spotted on the target plate and air dried. MS survey data comprises a total of 50 sub-spectra of 1500 laser shots. Peaks observed in the MS spectra were selected for further MS/MS. CID MS/MS data comprises a total of 100 sub-spectra of 3000 laser shots. Two or more spectra can be combined post-acquisition with mass tolerance set at 0.1 Da to improve S/N ratio. The potential difference between the source acceleration voltage and the collision cell was set to 1 kV and argon was used as collision gas.

3.7. Analysis of Oligo-Sialylated Sequences by HPLC

In order to minimize internal fragmentation of polysialylated sequences, sialylated glycan samples were directly coupled to 1,2-diamino-4,5-methylenedioxybenzene (DMB) without prior mild hydrolysis [35]. Samples were incubated for 2.5 h at 50 °C in 50 µL of a DMB reagent solution (2.7 mM DMB, 9 mM sodium hydrosulfite, and 0.5 mM β-mercaptoethanol in 20 mM TFA). 10 µL of 1 M NaOH was then added and the reaction mixtures further incubated in the dark at room temperature for 1 h. Samples were stored at 4 °C before analysis. DMB-derivatized sialic acid oligomers were separated on a HPLC apparatus fitted with a CarboPac PA-100 column (Dionex). CarboPac column was eluted at 1 mL/min with a concentration gradient of 2 to 32% of 1 M NaNO$_3$ in water. Elution was monitored by an on line fluorescence detector set at wavelengths of 373 nm for excitation and 448 nm for emission.

4. Conclusions

ST8Sia I is the only sialyltransferase able to transfer a sialic acid residue onto G$_{m3}$ to synthesize G$_{D3}$ and is therefore considered as the G$_{D3}$ synthase. The animal ST8Sia family can be divided in three groups according to the capacity to carry out poly-, oligo- and mono-α2,8-sialylation and phylogenetic analyses have clearly associated ST8Sia I to the group of mono-α2,8-sialyltransferase [41]. However, by expression cloning of the human G$_{T3}$ synthase, Nakayama and co-workers have underlined the ability of ST8Sia I to synthesize G$_{T3}$ from G$_{D3}$ [6]. Here, we show, for the first time, that ST8Sia I is able to synthesize unusual highly sialylated lactosylceramide derivatives substituted by up to
5 Neu5Ac residues and identified as GQ3 (II^3Neu5Ac-Gg2Cer) and GP3 (II^3Neu5Ac5-Gg2Cer), showing that this enzyme can act as an oligosialyltransferase.

In humans, the ST8SIA1 gene is located on chromosome 12, in p12.1-p11.2 and consists of five coding exons spanning over 135 kbp of genomic DNA [14]. Two initiation codons on the first exon lead to two protein isoforms of 356 or 341 amino acids that differ in their N-terminal part. However, the relative capacity of each isoform to transfer more than two sialic acid residues has not been evaluated. By *in vitro* sialyltransferase assay, a recombinant soluble form of the human GD3 synthase was shown to synthesize, after a long period of incubation, higher polysialogangliosides, which presumably have more than three sialic acid residues but these compounds were not characterized [6].

From a general point of view, the occurrence of oligosialylation associated with glycolipids has been rarely reported so far. One exception is the recent identification of polysialogangliosides containing α2,8-linked polyNeu5Ac with DPs ranging from 2 to at least 16 in sea urchin sperm head [42]. However, to our knowledge, tetra- and pentasialylated lactosylceramide derivatives have never been described in human tissues and cells. Although SK-Mel 28 cells that constitutively express high levels of GD3S, synthesize high quantities of G_D3 and G_T3, we were not able to detect these unusual tetra- and pentasialylated gangliosides in this cell line. Indeed, in our cellular model, these unusual structures were obtained after transfection of GD3S cDNA and may not exist in natural conditions, and the depletion of G_M3 in GD3S+ MCF-7 clones could explain that GD3S used other gangliosides, such as G_T3 or G_Q3, as acceptor substrates. Nevertheless, one may thus expect that revisiting the structure of human gangliosides with recent high sensitivity mass spectrometry techniques will uncover oligosialylated glycolipids in cancerous cell lines and in normal or pathological tissues.

Acknowledgments

This work was supported by the University of Sciences and Technologies of Lille, the Association pour la Recherche sur le Cancer (Grant n° 7936 and 5023) et le comité de l’Aisne de La Ligue contre le Cancer. Florent Colomb is supported by a PhD fellowship from “Vaincre la mucoviscidose”.

References

1. Svennerholm, L. Ganglioside designation. *Adv. Exp. Med. Biol.* 1980, 125, 11–19.
2. Zeng, G.; Yu, R.K. Cloning and transcriptional regulation of genes responsible for synthesis of gangliosides. *Curr. Drug Targets* 2008, 9, 317–324.
3. Yamamoto, A.; Haraguchi, M.; Yamashiro, S.; Fukumoto, S.; Furukawa, K.; Takamiya, K.; Atsuta, M.; Shiku, H.; Furukawa, K. Heterogeneity in the expression pattern of two ganglioside synthase genes during mouse brain development. *J. Neurochem.* 1996, 66, 26–34.
4. Yu, R.K.; Macala, L.J.; Taki, T.; Weinfield, H.M.; Yu, F.S. Developmental changes in ganglioside composition and synthesis in embryonic rat brain. *J. Neurochem.* 1988, 50, 1825–1829.
5. Yamashita, T.; Wada, R.; Sasaki, T.; Deng, C.; Bierfreund, U.; Sandhoff, K.; Proia, R.L. A vital role for glycosphingolipid synthesis during development and differentiation. *Proc. Natl. Acad. Sci. USA* 1999, 96, 9142–9147.
6. Nakayama, J.; Fukuda, M.N.; Hirabayashi, Y.; Kanamori, A.; Sasaki, K.; Nishi, T.; Fukuda, M. Expression cloning of a human GT3 synthase. GD3 and GT3 are synthesized by a single enzyme. J. Biol. Chem. 1996, 271, 3684–3691.

7. Furukawa, K.; Hamamura, K.; Aixinjueluo, W.; Furukawa, K. Biosignals modulated by tumor-associated carbohydrate antigens novel targets for cancer therapy. Ann. NY Acad. Sci. 2006, 1086, 185–198.

8. Oblinger, J.L.; Pearl, D.K.; Boardman, C.L.; Saqr, H.; Prior, T.W.; Scheithauer, B.W.; Jenkins, R.B.; Burger, P.C.; Yates, A.J. Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients. Neuropathol. Appl. Neurobiol. 2006, 32, 410–418.

9. Ruan, S.; Lloyd, K.O. Glycosylation pathways in the biosynthesis of gangliosides in melanoma and neuroblastoma cells relative glycosyltransferase levels determine ganglioside patterns. Cancer Res. 1992, 52, 5725–5731.

10. Ruckhäberle, E.; Rody, A.; Engels, K.; Gaetje, R.; von Minckwitz, G.; Schiffmann, S.; Grösch, S.; Geisslinger, G.; Holtrich, U.; Kern, T.; Kaufmann, M. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res. Treat. 2008, 112, 41–52.

11. Nara, K.; Watanabe, Y.; Maruyama, K.; Kasahara, K.; Nagai, Y.; Sanai, Y. Expression cloning of a CMP-NeuAcNeuAc alpha 2-3Gal beta 1-4Glc beta 1-1' Cer alpha 2,8-sialyltransferase (GD3 synthase) from human melanoma cells. Proc. Natl. Acad. Sci. USA 1994, 91, 7952–7956.

12. Sasaki, K.; Kurata, K.; Kojima, N.; Kurosawa, N.; Ohta, S.; Hanai, N.; Tsuji, S.; Nishi, T. Expression cloning of a GM3-specific alpha-2,8-sialyltransferase (GD3 synthase). J. Biol. Chem. 1994, 269, 15950–15956.

13. Haraguchi, M.; Yamashiro, S.; Yamamoto, A.; Furukawa, K.; Takamiya, K.; Lloyd, K.O.; Shiku, H.; Furukawa, K. Isolation of GD3 synthase gene by expression cloning of GM3 alpha-2,8-sialyltransferase cDNA using anti-GD2 monoclonal antibody. Proc. Natl. Acad. Sci. USA 1994, 91, 10455–10459.

14. Furukawa, K.; Horie, M.; Okutomi, K.; Sugano, S.; Furukawa, K. Isolation and functional analysis of the melanoma specific promoter region of human GD3 synthase gene. Biochim. Biophys. Acta 2003, 1627, 71–78.

15. Harduin-Lepers, A.; Vallejo-Ruiz, V.; Krzewinski-Recchi, M.A.; Samyn-Petit, B.; Julien, S.; Delannoy, P. The human sialyltransferase family. Biochimie 2001, 83, 727–737.

16. Nara, K.; Watanabe, Y.; Kawashima, I.; Tai, T.; Nagai, Y.; Sanai, Y. Acceptor substrate specificity of a cloned GD3 synthase that catalyzes the biosynthesis of both GD3 and GD1c/GT1a/GQ1b. Eur. J. Biochem. 1996, 238, 647–652.

17. Kim, Y.J.; Kim, K.S.; Do, S.; Kim, C.H.; Kim, S.K.; Lee, Y.C. Molecular cloning and expression of human alpha2,8-sialyltransferase (hST8Sia V). Biochem. Biophys. Res. Commun. 1997, 235, 327–330.

18. Ichikawa, S.; Sakiyama, H.; Suzuki, G.; Hidari, K.I.; Hirabayashi, Y. Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyzes the first glycosylation step of glycosphingolipid synthesis. Proc. Natl. Acad. Sci. USA 1996, 93, 4638–4643.

19. Nomura, T.; Takizawa, M.; Aoki, J.; Arai, H.; Inoue, K.; Wakasaka, E.; Yoshizuka, N.; Imokawa, G.; Dohmae, N.; Takio, K.; et al. Purification, cDNA cloning, and expression of UDP-Gal:
20. Takizawa, M.; Nomura, T.; Wakisaka, E.; Yoshizuka, N.; Aoki, J.; Arai, H.; Inoue, K.; Hattori, M.; Matsuo, N. cDNA cloning and expression of human lactosylceramide synthase. *Biochim. Biophys. Acta* 1999, 1438, 301–304.

21. Ishii, A.; Ohta, M.; Watanabe, Y.; Matsuda, K.; Ishiyama, K.; Sakoe, K.; Nakamura, M.; Inokuchi, J.; Sanai, Y.; Saito, M. Expression cloning and functional characterization of human cDNA for ganglioside GM3 synthase. *J. Biol. Chem.* 1998, 273, 31652–31655.

22. Nagata, Y.; Yamashiro, S.; Yodoi, J.; Lloyd, K.O.; Shiku, H.; Furukawa, K. Expression cloning of beta 1,4 N-acetylglactosaminyltransferase cDNAs that determine the expression of GM2 and GD2 gangliosides. *J. Biol. Chem.* 1992, 267, 12082–12089.

23. Iber, H.; Zacharias, C.; Sandhoff, K. The c-series gangliosides GT3, GT2 and GP1c are formed in rat liver Golgi by the same set of glycosyltransferases that catalyse the biosynthesis of asialo-, a- and b-series gangliosides. *Glycobiology* 1992, 2, 137–142.

24. Yamashiro, S.; Haraguchi, M.; Furukawa, K.; Takamiya, K.; Yamamoto, A.; Nagata, Y.; Lloyd, K.O.; Shiku, H.; Furukawa, K. Substrate specificity of beta 1,4-N-acetylgalactosaminyltransferase in vitro and in cDNA-transfected cells. GM2/GD2 synthase efficiently generates asialo-GM2 in certain cells. *J. Biol. Chem.* 1995, 270, 6149–6155.

25. Amado, M.; Almeida, R.; Carneiro, F.; Levery, S.B.; Holmes, E.H.; Nomoto, M.; Hollingsworth, M.A.; Hassan, H.; Schwientek, T.; Nielsen, P.A.; et al. A family of human beta3-galactosyltransferases. Characterization of four members of a UDP-galactose: Beta-N-acetyl-glucosamine/beta-N-acetyl-galactosamine beta-1,3-galactosyltransferase family. *J. Biol. Chem.* 1998, 273, 12770–12778.

26. Kitagawa, H.; Paulson, J.C. Differential expression of five sialyltransferase genes in human tissues. *J. Biol. Chem.* 1994, 269, 17872–17878.

27. Giordanengo, V.; Bannwarth, S.; Laffont, C.; van Miegem, V.; Harduin-Lepers, A.; Delannoy, P.; Lefebvre, J.C. Cloning and expression of cDNA for a human Gal(bet1-3)GalNAc alpha2,3-sialyltransferase from the CEM T-cell line. *Eur. J. Biochem.* 1997, 247, 558–566.

28. Tsuchida, A.; Ogiso, M.; Nakamura, Y.; Kiso, M.; Furukawa, K.; Furukawa, K. Molecular cloning and expression of human ST6GalNAc III: Restricted tissue distribution and substrate specificity. *J. Biochem.* 2005, 138, 237–243.

29. Harduin-Lepers, A.; Mollicone, R.; Delannoy, P.; Oriol, R. The animal sialyltransferases and sialyltransferase-related genes: A phylogenetic approach. *Glycobiology* 2005, 15, 805–817.

30. Cazet, A.; Groux-Degroote, S.; Teylaert, B.; Kwon, K.M.; Lehoux, S.; Slomianny, C.; Kim, C.H.; Le Bourhis, X.; Delannoy, P. GD3 synthase overexpression enhances proliferation and migration of MDA-MB-231 breast cancer cells. *Biol. Chem.* 2009, 390, 601–609.

31. Ruan, S.; Raj, B.K.; Lloyd, K.O. Relationship of glycosyltransferases and mRNA levels to ganglioside expression in neuroblastoma and melanoma cells. *J. Neurochem.* 1999, 72, 514–521.

32. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. *Methods* 2001, 25, 402–408.
33. Steenackers, A.; Cazet, A.; Bobowski, M.; Rombouts, Y.; Lefebvre, J.; Guérardel, Y.; Tulasne, D.; Le Bourhis, X.; Delannoy, P. Expression of GD3 synthase modifies ganglioside profile and increases migration of MCF-7 breast cancer cells. *C.R. Chim.* 2012, 15, 3–14.

34. Domon, B.; Costello, C.E. A systematic nomenclature for carbohydrate fragmentations in FAB-MS/MS spectra of glycoconjugates. *Glycoconj. J.* 1988, 5, 397–409.

35. Sato, C.; Inoue, S.; Matsuda, T.; Kitajima, K. Fluorescent-assisted detection of oligosialyl units in glycoconjugates. *Anal. Biochem.* 1999, 266, 102–109.

36. Chang, L.-Y.; Harduin-Lepers, A.; Kitajima, K.; Sato, C.; Huang, C.-J.; Khoo, K.-H.; Guérardel, Y. Developmental regulation of oligosialylation in zebrafish. *Glycoconj. J.* 2009, 26, 247–261.

37. Moon, S.K.; Kim, H.M.; Lee, Y.C.; Kim, C.H. Disialoganglioside (GD3) synthase gene expression suppresses vascular smooth muscle cell responses via the inhibition of ERK1/2 phosphorylation, cell cycle progression, and matrix metalloproteinase-9 expression. *J. Biol. Chem.* 2004, 279, 33063–33070.

38. Zhang, X.; Ding, L.; Sandford, A.J. Selection of reference genes for gene expression studies in human neutrophils by real-time PCR. *BMC Mol. Biol.* 2005, 6, 4.

39. Schnaar, R.L. Isolation of glycosphingolipids. *Methods Enzymol.* 1994, 230, 348–370.

40. Ciucanu, I.; Kerek, F. Rapid and simultaneous methylation of fatty and hydroxy fatty acids for gas-liquid chromatographic analysis. *J. Chromatogr.* 1984, 284, 179–185.

41. Harduin-Lepers, A.; Petit, D.; Mollicone, R.; Delannoy, P.; Petit, J.-M.; Oriol, R. Evolutionary history of the alpha2,8-sialyltransferase (ST8Sia) gene family: Tandem duplications in early deuterostomes explain most of the diversity found in the vertebrate ST8Sia genes. *BMC Evol. Biol.* 2008, 8, 258.

42. Miyata, S.; Yamakawa, N.; Toriyama, M.; Sato, C.; Kitajima, K. Co-expression of two distinct polysialic acids, α2,8- and α2,9-linked polymers of N-acetylneuraminic acid, in distinct glycoproteins and glycolipids in sea urchin sperm. *Glycobiology* 2011, 21, 1596–1605.

Sample Availability: Not available.

© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).